Taiwan Advance Bio-Pharmaceutical Inc. (TPEX:4186)
Taiwan · Delayed Price · Currency is TWD 7.95
-0.07 (-0.87%)
Aug 26, 2026, 12:14 PM CST
TPEX:4186 Financials Overview
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 348.54 | 364.79 | 354.17 | 315.98 | 318.24 | 243.36 |
Revenue Growth | -4.45% | 3.00% | 12.09% | -0.71% | 30.77% | 3.31% |
Gross Profit Gross Profit Growth | 213.66 | 234.07 | 243.97 | 198.46 | 192.58 | 124.79 |
Operating Income Operating Income Growth | 26.77 | 37.39 | 44.84 | 4.27 | 7.61 | -102.79 |
Net Income Net Income Growth | 15.76 | 28.05 | 22.88 | -10.68 | 3.17 | -118.53 |
Earnings Per Share EPS Growth | 0.18 | 0.31 | 0.25 | -0.12 | 0.04 | -1.32 |
EPS Growth | -41.66% | 24.00% | - | - | - | - |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
New Business Division New Business Division Growth | 88.68 | 94.87 | - | - | - |
Inspection Business Division Inspection Business Division Growth | 94.92 | 82.61 | 75.89 | 77.94 | 62.94 |
Precise Medical Division Precise Medical Division Growth | 143.55 | 146.06 | 200.91 | 188.42 | 130.03 |
Food Safety Business Division Food Safety Business Division Growth | 37.64 | 30.63 | 39.19 | 51.88 | 50.4 |
Total Total Growth | 364.79 | 354.17 | 315.98 | 318.24 | 243.36 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 157.98 | 140.74 | 106.32 | 182.14 | 158.56 | 159.7 |
Total Debt Total Debt Growth | 279.69 | 264.12 | 229.64 | 307.24 | 279.7 | 248.97 |
Net Cash (Debt) Net Cash Growth | -121.71 | -123.38 | -123.32 | -125.11 | -121.15 | -89.27 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -1.41 | -1.37 | -1.37 | -1.39 | -1.35 | -0.99 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 54.56 | 53.13 | 8.33 | 12.61 | -20.59 | -48.08 |
Capital Expenditures CapEx Growth | -35.68 | -33.36 | -3.96 | -11.94 | -7.28 | -15.19 |
Free Cash Flow Free Cash Flow Growth | 18.88 | 19.77 | 4.37 | 0.67 | -27.87 | -63.28 |
Free Cash Flow Growth | -4.50% | 352.74% | 554.72% | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 61.30% | 64.17% | 68.88% | 62.80% | 60.51% | 51.28% |
Operating Margin | 7.68% | 10.25% | 12.66% | 1.35% | 2.39% | -42.24% |
Pretax Margin | 4.27% | 7.44% | 6.38% | -3.60% | 1.16% | -47.03% |
Profit Margin | 4.52% | 7.69% | 6.46% | -3.38% | 1.00% | -48.70% |
FCF Margin | 5.42% | 5.42% | 1.23% | 0.21% | -8.76% | -26.00% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 26, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 43.96 | 35.78 | 61.97 | - | 502.52 | - |
P/FCF Ratio | 37.89 | 50.76 | 324.59 | 2226.39 | - | - |
PS Ratio | 2.05 | 2.75 | 4.00 | 4.70 | 5.01 | 6.88 |